Share Email Print

Proceedings Paper

Stage III endobronchial squamous cell cancer: survival after Nd:YAG laser combined with photodynamic therapy versus Nd:YAG laser or photodynamic therapy alone
Author(s): James S. McCaughan M.D.; Rostislav D. Barabash; Philip Hawley M.D.
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Eighty-eight patients with stage III endobronchial squamous cell cancer were treated with Nd:YAG laser therapy alone (49), photodynamic therapy (PDT) alone (14), or a combination of Nd:YAG and PDT therapy (25). Mean survival rates were as follows: PDT equals 4.8 months, Nd:YAG therapy equals 3.3 months, PDT followed by Nd:YAG equals 10.9 months, Nd:YAG followed by PDT equals 9.0 months, and all combination therapy equals 9.2 months. The difference between survival rates for combination therapy and Nd:YAG only was statistically significant (P equals 0.003). The authors recommend a combination of PDT and Nd:YAG laser therapies in patients who have undergone or are not amenable to conventional therapies for this tumor. Further, the authors recommend that these patients be treated early, before the tumor spreads to other bronchi or becomes large and bloody, in order to reduce the risk for perioperative complications.

Paper Details

Date Published: 1 June 1991
PDF: 8 pages
Proc. SPIE 1426, Optical Methods for Tumor Treatment and Early Diagnosis: Mechanisms and Techniques, (1 June 1991); doi: 10.1117/12.44067
Show Author Affiliations
James S. McCaughan M.D., Laser Medical Research Foundation (United States)
Rostislav D. Barabash, Laser Medical Research Foundation (United States)
Philip Hawley M.D., Laser Medical Research Foundation (United States)

Published in SPIE Proceedings Vol. 1426:
Optical Methods for Tumor Treatment and Early Diagnosis: Mechanisms and Techniques
Thomas J. Dougherty, Editor(s)

© SPIE. Terms of Use
Back to Top